Norinchukin Bank The Acquires 465 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Norinchukin Bank The grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,756 shares of the biopharmaceutical company’s stock after purchasing an additional 465 shares during the quarter. Norinchukin Bank The’s holdings in Regeneron Pharmaceuticals were worth $4,616,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the company. Ironwood Wealth Management LLC. lifted its stake in shares of Regeneron Pharmaceuticals by 17.5% in the fourth quarter. Ironwood Wealth Management LLC. now owns 235 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 35 shares during the period. Focused Wealth Management Inc increased its holdings in Regeneron Pharmaceuticals by 101.4% in the fourth quarter. Focused Wealth Management Inc now owns 54 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 4,045 shares in the last quarter. CIBC Asset Management Inc increased its holdings in Regeneron Pharmaceuticals by 7.0% in the fourth quarter. CIBC Asset Management Inc now owns 19,534 shares of the biopharmaceutical company’s stock worth $9,437,000 after purchasing an additional 1,277 shares in the last quarter. Reilly Financial Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 212.1% in the fourth quarter. Reilly Financial Advisors LLC now owns 103 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 70 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. increased its holdings in Regeneron Pharmaceuticals by 25.9% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 13,727 shares of the biopharmaceutical company’s stock worth $6,632,000 after purchasing an additional 2,823 shares in the last quarter. 83.03% of the stock is currently owned by hedge funds and other institutional investors.

REGN opened at $532.04 on Friday. The stock has a market cap of $56.69 billion, a PE ratio of 15.06, a PEG ratio of 0.58 and a beta of 0.20. The company has a current ratio of 3.12, a quick ratio of 2.45 and a debt-to-equity ratio of 0.17. The company has a 50 day moving average price of $497.98. Regeneron Pharmaceuticals, Inc. has a 52 week low of $441.00 and a 52 week high of $664.64.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 6th. The biopharmaceutical company reported $9.89 EPS for the quarter, topping the Zacks’ consensus estimate of $7.78 by $2.11. The business had revenue of $2.53 billion during the quarter, compared to analyst estimates of $2.69 billion. Regeneron Pharmaceuticals had a return on equity of 35.43% and a net margin of 43.53%. The company’s quarterly revenue was up 38.3% compared to the same quarter last year. During the same quarter last year, the company earned $6.60 EPS. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 46.81 EPS for the current fiscal year.

In related news, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, May 7th. The stock was sold at an average price of $495.63, for a total value of $495,630.00. Following the completion of the sale, the executive vice president now owns 18,038 shares of the company’s stock, valued at $8,940,173.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 10.76% of the company’s stock.

A number of equities research analysts have weighed in on REGN shares. SVB Leerink lowered their target price on Regeneron Pharmaceuticals from $657.00 to $641.00 and set an “outperform” rating for the company in a report on Friday, May 7th. Credit Suisse Group boosted their price objective on Regeneron Pharmaceuticals from $753.00 to $760.00 and gave the company an “outperform” rating in a report on Tuesday, February 23rd. Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $477.00 to $495.00 and gave the company an “equal weight” rating in a report on Friday, May 7th. Cantor Fitzgerald cut their price objective on Regeneron Pharmaceuticals from $696.00 to $656.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 16th. Finally, Robert W. Baird reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 13th. Four analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $657.95.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Article: What is Compound Interest?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.